A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
|Videos|November 3, 2021
AD and Age: What to Look Forward to at ACAAI
Author(s)Linda Stocum, Associate Editor
Jonathan M. Spergel, MD, PhD, FACAAI discusses what there is to look forward to at the ACAAI conference and what he's highlighting at the event.
Advertisement
In this video interview, Jonathan M. Spergel, MD, PhD, FACAAI talks on what he believes is the best part of the American College of Allergy, Asthma, and Immunology (ACAAI) conference, happening in New Orleans, Louisiana November 4 through the 8. He also tells us what we have to look forward to from his talks at the event.
Advertisement
Related to this article
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5